Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Google Secures Pentagon AI Deal for Classified Projects 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
-- Investor breakfast event and webcast at ASGCT on Friday, May 12 at 7:00 a.m. EDT --
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferences taking place in May:
American Society of Gene and Cell Therapy (ASGCT), May 10 – 13 2017, at the Marriott Wardman Park hotel in Washington, D.C.
- Five abstracts have been accepted for presentation at the ASGCT meeting. Together with their collaborators, members of uniQure’s research and development team will present data focused on progress in re-administration protocols, gene therapy delivery systems and optimized vector distribution technologies in two of uniQure’s key programs, hemophilia-B and Huntington’s disease.
- In addition, uniQure management will host an investor and analyst breakfast meeting & webcast featuring senior leaders of its research and development team. To request attendance at the meeting, taking place at May 12, 2017 at 7:00 a.m. EDT, please RSVP to [email protected] by May 5, 2017, as space is limited.
- The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.
UBS Global Healthcare Conference, May 22 – 24 2017, at the Grand Hyatt New York, in New York City.
- Matthew Kapusta, chief executive officer, will present on Tuesday, May 23rd, 2017 at 3:00 p.m. EDT. The live webcast can be accessed through the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/events-presentations.php. The webcast replay will be available for at least two weeks following the live event.
American Biomanufacturing Summit, May 23 – 24 2017, at the Hyatt Regency Mission Bay Spa & Marina, in San Diego, California.
- Lance Weed, Vice President of US Operations, will be presenting: Developing a Scalable Disposable Manufacturing Facility for Producing Gene Therapies, on May 24 at 3:00 p.m. PT. uniQure's Lexington-based facility is one of the largest, most versatile gene therapy manufacturing facilities in the world, with state-of-the-art commercial-scale production capabilities that utilize 100% single-use components.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com.
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
